ESA Biosciences and Waters Corporation Announce Collaboration
News Mar 27, 2008
ESA Biosciences and Waters Corporation have announced that the two companies are working together to integrate the ESA Corona® CAD® universal HPLC detector with the Waters chromatography control and data-analysis platform: Empower® 2.
The Corona charged-aerosol detector (CAD) can analyze a wide diversity of chemical structures and important classes of molecules - from small organic molecules, proteins and peptides, to ions, carbohydrates, lipids, and polymers.
Many scientists in the pharmaceutical industry already combine a Waters Empower 2 software-controlled LC System with the Corona CAD detector for applications ranging from excipient and formulation characterization and forced-degradation studies to impurity analysis, cleaning validations, and final product QC.
"In working with ESA Biosciences, we are responding to the needs of our Empower 2 software users who are using the Corona CAD for their applications. By adding a new feature into our Empower software to control ESA's detector, we're giving our customers more choices and more ways to be successful," said Bill Foley, Director - Product Marketing, Waters Corporation.
ESA's Vice President of Life Sciences Marketing, Jasmine Gruia-Gray, said, "We listen closely to customer suggestions for product enhancements - a key part our commitment to continuously improve results and help scientists do their jobs better, faster, and easier. Customers have asked for a direct interface between the Corona CAD and Empower platforms. We're pleased to work with Waters so we can meet our respective customers' needs."
As genome editing technologies advance toward clinical therapies, they are raising hopes of a completely new way to treat disease. However, challenges need to be addressed before potential treatments can be widely used in patients. To tackle these challenges, the National Institutes of Health has launched the Somatic Cell Genome Editing program, which has awarded multiple grants including more than $3.6 million to assess the safety of genome editing in human cells and tissues.